A Chinese research study of diabetes patients with coronary heart disease concluded that metformin is more effective than glipizide in reducing the risk of major cardiovascular events, such as stroke and heart attack.
Researchers at the Shanghai Jiao Tong University School of Medicine studied 304 patients, ages 36 to 80, over a five-year period. The patients were randomly assigned either the sulfonylurea glipizide (30 mg daily) or metformin (1.5 g daily) for three years, according to Diabetes Health Staff. Researchers said that this was the first known head-to-head comparison of the two drugs’ ability to affect the incidence of cardio-vascular events. One explanation for metformin’s superior performance may be that it has anti-atherosclerotic properties-the ability to help blood vessels resist the hardening associated with diabetic inflammation.
This news item first appeared in our free-to-receive online magazine. Go to the home page of this website to sign up – we just need your email address.